论文部分内容阅读
目的:探讨高原肺动脉高压病血清肌钙蛋白Ⅰ(cTnI)水平,分析高原肺动脉高压病与血清肌钙蛋白Ⅰ(cTnI)的相关性。方法:采用美国Nano_Checker710法定量测定血清cTnI。结果:本研究健康人血清cTnI测定结果为(0.61±0.10)ng/mL;高原肺动脉高压病人群cTnI为(1.42±0.16)ng/mL,差异非常显著,具有统计学意义(P<0.01)。结论:高原肺动脉高压病人群血清cTnI含量明显升高,为进一步预防、诊治高原肺动脉高压病提供参考依据。
Objective: To investigate the serum level of troponin Ⅰ (cTnI) in patients with high altitude pulmonary hypertension and to analyze the relationship between altitude pulmonary hypertension and serum troponin Ⅰ (cTnI). Methods: Serum cTnI was determined by the Nano_Checker710 method in the United States. Results: The serum cTnI in healthy volunteers was (0.61 ± 0.10) ng / mL in this study. The cTnI in high altitude patients with pulmonary hypertension was (1.42 ± 0.16) ng / mL, the difference was statistically significant (P <0.01). Conclusion: Serum cTnI levels in patients with high altitude pulmonary hypertension are significantly increased, which may provide reference for further prevention, diagnosis and treatment of altitude pulmonary hypertension.